In vivo inhibition of angiotensin converting enzyme and neutral endopeptidase by a dual vasopeptidase inhibitor

被引：0
|
作者：
Burrell, LM
Rockell, MD
Powell, J
Johnston, CI
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
来源：
AMERICAN JOURNAL OF HYPERTENSION | 1999年 / 12卷 / 04期
关键词：
vasopeptidase inhibitors; omapatrilat; angiotensin; natriuretic peptides;
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：119A / 119A
页数：1
相关论文
共 50 条
  • [41] Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses
    Gardner, SY
    Atkins, CE
    Sams, RA
    Schwabenton, AB
    Papich, MG
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2004, 18 (02) : 231 - 237
  • [42] Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice
    Akishita, M
    Shirakami, G
    Iwai, M
    Wu, L
    Aoki, M
    Zhang, LN
    Toba, K
    Horiuchi, M
    JOURNAL OF HYPERTENSION, 2001, 19 (06) : 1083 - 1088
  • [43] Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit
    Sahin, Y
    Kontas, O
    Muderris, II
    Cankurtaran, M
    GYNECOLOGICAL ENDOCRINOLOGY, 1997, 11 (04) : 231 - 236
  • [44] Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients
    Hara, Y
    Hamada, M
    Shigematsu, Y
    Ohtsuka, T
    Hiwada, K
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2002, 27 (04) : 267 - 271
  • [45] Inhibitor of angiotensin-converting enzyme modifies myointimal origin in an arterial autograft model
    Bujan, J
    Bellon, JM
    Jurado, F
    Dominguez, B
    Gimeno, MJ
    GarciaHonduvilla, N
    Hernando, A
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (02) : 285 - 293
  • [46] Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient
    Jarred, Ghassan
    Kennedy, R. Lee
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2010, 1 (01) : 23 - 28
  • [47] Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
    Brugts, Jasper J.
    Simoons, Maarten L.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (08) : 1001 - 1009
  • [48] Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure
    Yasuda, S
    Goto, Y
    Sumida, H
    Noguchi, T
    Baba, T
    Miyazaki, S
    Nonogi, H
    HYPERTENSION, 1999, 33 (06) : 1374 - 1378
  • [49] Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension
    Rasoul, S
    Carretero, OA
    Peng, HM
    Cavasin, MA
    Zhuo, JL
    Sanchez-Mendoza, A
    Brigstock, DR
    Rhaleb, NE
    JOURNAL OF HYPERTENSION, 2004, 22 (03) : 593 - 603
  • [50] COMPARISON OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION WITH ANGIOTENSIN-II RECEPTOR ANTAGONISM IN THE HUMAN FOREARM
    COCKCROFT, JR
    SCIBERRAS, DG
    GOLDBERG, MR
    RITTER, JM
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 22 (04) : 579 - 584
12345